One of the most promising cell-based immunotherapy cancer treatments is CAR T-cell therapy (Chimeric Antigen Receptor T-cell Therapy). The treatment involves:

• Removing immune system T-cells from the blood stream

• Shipping T-cell product to a manufacturing laboratory

• Genetically engineer (reprogram) T-cells to produce special receptors on their surface called Chimeric Antigen Receptors, or CARs. This enables the T-cells to better recognize and kill cancer cells.

• Expand T-cells to make billions of new enhanced T-cells.

• Infuse the CAR T-cell product back into the patient to target and kill malignant cancer cells.

Please review our NSH Immunotherapy Program pamphlet for additional information.

Future FDA-approved CAR T-cell disease indications will become available soon. Current and future clinical research studies involving the use of CAR T-cell therapy in leukemia, lymphoma, and myeloma will be ongoing.